Abstract: Objective To investigate the effect of Entecavir in the treatment of liver cirrhosis and hepatogenic diabetes in patients with hepatitis B and its influence on liver function index and liver fibrosis index. Methods From October,2012 to October,2014,72 cases of liver cirrhosis and hepatogenic diabetes caused by hepatitis B in our hospital were treated,and were randomly divided into observation group (36 cases) and control group (36 cases) according to the random number table method.The control group received routine treatment,while the observation group received additional Entecavir on the basis of the treatment in the control group.The courses of both groups were 12 months.The liver function indexes,glucose metabolism indexes,liver fibrosis indexes and adverse reactions of the two groups were compared. Results Alb level of both groups were significantly increased,ALT and TBiL were significantly decreased after the treatment (P<0.05);After Alb treatment,the observation group was significantly higher than the control group,ALT,TBiL after the treatment was significantly lower than that of the control group (P<0.05);The fasting blood glucose,two-hour postprandial blood sugar,and HbA1c after the treatment in both groups was significantly reduced (P<0.05);Fasting blood glucose,two-hour postprandial blood sugar and HbA1c in the observation group were significantly lower than those in the control group (P<0.05);PCⅢ,HA and LN after the treatment of both groups was significantly reduced (P<0.05);PCⅢ,HA and LN after the treatment of the observation group was significantly lower than those in the control group (P<0.05);No serious adverse reactions were found in the two groups,and the liver function was not increased. Conclusion The effect of Entecavir in the treatment of liver cirrhosis and hepatogenic diabetes in patients with hepatitis B is obvious,it can significantly improve the liver function and hepatic fibrosis indexes of patients.So its clinical value is important.